Loading insider details...
Beta
Latest Form 4 (Aug 24, 2026): Sale of 19,890 NTLA shares, $250.6K.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Company | Transaction | Shares | Value |
|---|---|---|---|---|
| Aug 24, 2026 | Intellia Therapeutics, Inc. (NTLA) | Sale | 19,890 | $250.6K |
| Apr 27, 2026 | IQVIA HOLDINGS INC. (IQV) | Grant/Award | 1,571 | n/a |
| Mar 3, 2026 | Intellia Therapeutics, Inc. (NTLA) | Grant/Award | 156,400 | n/a |
| Jan 7, 2026 | Intellia Therapeutics, Inc. (NTLA) | Sale | 34,146 | $314.5K |
| Dec 12, 2025 | Intellia Therapeutics, Inc. (NTLA) | Exercise/Conversion | 49,959 | $341.2K |
| Apr 25, 2025 | IQVIA HOLDINGS INC. (IQV) | Grant/Award | 1,592 | n/a |
| Mar 4, 2025 | Intellia Therapeutics, Inc. (NTLA) | Grant/Award | 136,000 | n/a |
| Jan 7, 2025 | Intellia Therapeutics, Inc. (NTLA) | Sale | 26,807 | $326.5K |
| Jan 3, 2025 | Intellia Therapeutics, Inc. (NTLA) | Exercise/Conversion | 7,850 | n/a |
| May 9, 2024 | IQVIA HOLDINGS INC. (IQV) | Grant/Award | 1,047 | n/a |